aTyr Pharma, Inc.(ATYR) - 2025 Q1 - Quarterly Results

Clinical Trials - Topline data from the Phase 3 EFZO-FIT™ study of efzofitimod in pulmonary sarcoidosis is expected to be announced in the third quarter of 2025[1] - The Phase 3 EFZO-FIT™ study enrolled 268 patients across 85 centers in nine countries, with a primary endpoint focused on steroid reduction from baseline to week 48[4] - Interim data from the Phase 2 EFZO-CONNECT™ study is expected in the second quarter of 2025, focusing on skin assessments in approximately eight patients[6] Financial Performance - Cash, cash equivalents, restricted cash, and available-for-sale investments as of March 31, 2025, were $78.8 million, sufficient to fund operations for one year post-Phase 3 EFZO-FIT™ readout[5] - Research and development expenses for the first quarter of 2025 were $11.8 million, primarily for clinical trial costs related to the EFZO-FIT™ and EFZO-CONNECT™ studies[10] - General and administrative expenses for the first quarter of 2025 totaled $4.0 million[10] - The consolidated net loss for the first quarter of 2025 was $14.9 million, compared to a net loss of $15.5 million in the same period of 2024[13] - The total operating expenses for the first quarter of 2025 were $15.8 million, a decrease from $16.9 million in the first quarter of 2024[13] - Total assets as of March 31, 2025, were $97.2 million, with total stockholders' equity of $74.9 million[15] Leadership Changes - The company appointed Dalia R. Rayes as Head of Commercial for the Global Efzofitimod Franchise, bringing over 25 years of experience in biotechnology and pharmaceutical sectors[6]